Prognosis
Pfizer Vaccine Gives 100% Protection at Ages 12-15 in Study
- Company will seek to add adolescents to its FDA authorization
- Result could pave way for shots in teens before school reopens
This article is for subscribers only.
Pfizer Inc. said its Covid-19 vaccine was 100% effective in a final-stage trial in kids ages 12 to 15, a finding that could pave the way for teens and pre-teens to get shots before the next school year.
The vaccine is already authorized in the U.S. for people ages 16 and up. Pfizer and its partner BioNTech SE said they planned to submit the data to regulators in the U.S and Europe as soon as possible, seeking to amend their vaccine authorizations to include the younger age group.